CJC-1295 Reconstitution & Dosage Calculator
Synthetic GHRH analog available in no DAC (short-acting) and DAC (long-acting) forms. Most commonly used as no DAC with Ipamorelin.
CJC-1295 Reconstitution Calculator
Pre-filled with standard CJC-1295 values. Adjust as needed.
CJC-1295 Dosing Guide
No DAC: 100–200mcg with Ipamorelin 1–3x daily. With DAC: 2mg 1–2x weekly. Always inject both peptides simultaneously for synergistic GH pulse.
Blood markers to track
Note: No DAC = Mod GRF 1-29 (30 min half-life). With DAC = 7-day half-life. Most protocols use no DAC for pulse-like GH release.
Deep Dive
From vial to syringe unit: the CJC-1295 reconstitution math
Every number this calculator returns comes from two inputs you supply: the peptide mass in the vial and the volume of bacteriostatic water you dissolve it in. Those two figures set the concentration, and concentration is what converts a clinician-set dose in micrograms into a mark you can actually read on an insulin syringe.
The arithmetic runs in three steps. First, concentration equals vial mass divided by water volume. A standard CJC-1295 (no DAC / Mod GRF 1-29) vial holds 2mg, which is 2000mcg. Reconstitute it with 2mL of bacteriostatic water and the concentration is 2000mcg divided by 2mL, or 1000mcg per mL. Second, injection volume equals target dose divided by concentration: a 100mcg dose is 100 divided by 1000, which is 0.1mL. Third, convert volume to units. A U-100 insulin syringe is marked so that 1mL equals 100 units, so 1 unit equals 0.01mL, and 0.1mL is 10 units. Double the dose to 200mcg and the draw doubles to 0.2mL, or 20 units. That is the entire calculation the tool performs.
The water volume you choose is a resolution decision, not a fixed rule. Dissolve the same 2mg vial in 1mL and the concentration doubles to 2000mcg per mL, so 100mcg now sits at only 5 units, a smaller and harder-to-read mark. The long-acting DAC form makes the trade-off vivid: a 2mg weekly DAC amount drawn from a 1000mcg per mL fill would consume the entire vial in one draw. Matching fill volume to dose size is why the calculator asks for both.
Why 10 units is not 10 micrograms
The single most common conceptual error is reading syringe units as if they were micrograms of peptide. They are not. Units are volume marks. Ten units means 0.1mL of liquid; how much CJC-1295 sits in that 0.1mL depends entirely on the concentration you created at reconstitution. Change the water volume and the micrograms per unit changes with it, even though the syringe looks identical.
Because GHRH-analog doses are small, 100 to 200mcg lands at just 10 to 20 units on a U-100 syringe, so any percentage error is amplified. Frequent mistakes:
- Confusing milligrams and micrograms. The vial reads 2mg but the dose is 100mcg, a 1000-fold gap. - Using a different water volume than the units were computed for. Reconstitute in 1mL when the tool assumed 2mL and every unit now carries twice the peptide. - Drawing on the wrong syringe scale. U-40 and U-100 syringes are not interchangeable; the same volume reads differently on each. - Parallax and air bubbles. On a 10-unit draw, a stray gap or an off-angle read is a large fraction of the dose.
The safeguard is simple: re-run the calculator whenever any input changes, and confirm the syringe is U-100 before trusting the unit figure.
Half-life is the reason for the schedule
CJC-1295 comes in two pharmacologically distinct forms, and dosing frequency follows directly from half-life. The no-DAC form (Mod GRF 1-29) clears in roughly 30 minutes. That short window is the point: it produces a discrete growth-hormone pulse and then returns to baseline, preserving the pulsatile rhythm of the GH axis, which is why no-DAC protocols are dosed one to three times daily rather than once and forgotten.
The DAC (Drug Affinity Complex) form carries a chemical group that binds serum albumin, stretching its half-life to roughly a week. In a 2006 study by Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism, a single subcutaneous DAC dose raised GH and IGF-1 for several days, with an estimated half-life of 5.8 to 8.1 days, which is the basis for once- or twice-weekly dosing. A companion study by Ionescu and Frohman found the DAC form left the frequency and magnitude of GH pulses unaltered while markedly raising basal (trough) GH, so total exposure is more continuous than the clean pulse-and-clear pattern of the short form. The calculator handles either; the frequency paired with each form is a pharmacokinetic consequence, not a preference.
Response-guided adjustment, not stepwise escalation
Titration means different things for different compounds, and the calculator supports both patterns. GLP-1 agonists such as tirzepatide follow a fixed tolerance-driven schedule, starting at 2.5mg once weekly and stepping up by 2.5mg roughly every four weeks to manage gastrointestinal side effects during dose escalation. GHRH analogs like CJC-1295 are not escalated on a calendar. Any dose change a clinician makes is response-guided, read from bloodwork rather than a preset ramp. When that dose changes, the calculator simply re-derives the new unit mark from the same concentration, so the work here is mechanical, not a dosing recommendation.
Biomarkers that show the dose is working and safe
Because CJC-1295 acts upstream on the GH axis, you cannot judge it by how you feel. The tracking markers do that job. IGF-1 is the primary downstream readout: GH drives hepatic IGF-1, so an IGF-1 draw several weeks in reflects whether the current dose is producing a biological effect, and a clinician reads that value against the age-adjusted reference range rather than treating a supraphysiologic level as a target. IGFBP-3 is IGF-1's main carrier protein, and the IGF-1 to IGFBP-3 relationship adds context on bioavailable IGF-1. Fasting glucose and HbA1c are the safety pair: GH is counter-regulatory to insulin, so sustained stimulation can nudge glucose control in the wrong direction, and these two markers catch that drift early. Logging all four over time is what turns the calculator's dose into an interpretable response curve. Dose decisions themselves belong to a licensed clinician.
Reconstitution, storage, and handling
Good technique protects the potency the math assumes. Bacteriostatic water is added slowly, running down the inside wall of the vial rather than jetting directly onto the lyophilized powder, which can foam and denature the peptide. Gentle swirling dissolves it; shaking does not help and can shear the molecule. Bacteriostatic water contains 0.9 percent benzyl alcohol, which lets a multi-use vial be drawn from over roughly a 28-day window; plain sterile water has no preservative and suits single use only. Once reconstituted, the vial is kept refrigerated at 2 to 8 degrees Celsius, out of light, and away from repeated freeze-thaw cycles. The dry lyophilized powder is comparatively stable before reconstitution but is still best kept cool and dark. A cloudy or expired vial is discarded on the schedule the preservative window and a clinician dictate rather than pushed past it.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
Frequently Asked Questions
What is the standard CJC-1295 dose?
No DAC: 100–200mcg with Ipamorelin 1–3x daily. With DAC: 2mg 1–2x weekly. Always inject both peptides simultaneously for synergistic GH pulse.
How do I reconstitute CJC-1295?
Add 2mL of bacteriostatic water to a 2mg vial of CJC-1295 to get a concentration of 1000 mcg/mL. This gives 100mcg per 10 units on a 100-unit insulin syringe.
What blood markers should I track while running CJC-1295?
Common biomarkers tracked alongside CJC-1295 protocols include IGF-1, IGFBP-3, Fasting glucose, HbA1c. Establishing a baseline panel before starting and re-drawing labs at consistent intervals lets you measure changes against your own reference point, generic lab ranges are less informative than your personal trend over time. MyProtocolStack tracks each of these biomarkers in the context of your active CJC-1295 protocol.
Last reviewed: June 2026. For education and tracking only, not medical advice. Confirm any dose with a licensed healthcare provider.
You have the dose. Now track whether it’s doing anything.
Log every CJC-1295 injection alongside your IGF-1and IGFBP-3 readings. Compare draws over time in your free dashboard, so the next change you make is based on your numbers, not a guess.
Start tracking CJC-1295 free →No credit card · Free forever tier